Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Edwards Lifesciences Corp(EW)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EW
09/25/2026: EW (1-star) is currently NOT-A-BUY. Pass it for now.
Edwards Lifesciences is a preeminent medical device company focused on structural heart therapies, particularly transcatheter heart valve replacement and repair technologies. The company is known for its high-margin profile and a proven track record of clinical innovation, which has established it as a major player in the global cardiovascular space. Its growth narrative is centered on the ongoing adoption of minimally invasive procedures for a widening range of patients. While its market leadership and strong clinical evidence are distinct strengths, the company faces notable competition and risks related to product concentration and regulatory pressures. It is best suited for growth-oriented investors looking for exposure to specialized healthcare innovation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Edwards is a primary player in the expanding structural heart market, offering sustained growth potential through innovative medical devices. |
| Momentum investor | Strong fit while signal remains positive | The company's stock often responds positively to clinical trial successes and regulatory approvals for its heart valve platforms. |
| Value investor | Mixed fit | The shares typically command a premium valuation due to high growth prospects, which may limit appeal for traditional value-oriented investors. |
| Dividend investor | Weak fit | Edwards does not pay a dividend, making it unsuitable for investors seeking regular income streams. |
| Low-risk investor | Mixed fit | While the business quality is high, the stock's sensitivity to sector-specific regulatory news and high growth multiples can induce price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | As a high-growth medical device stock, EW can experience significant price swings based on trial results and competitive updates. |
| Valuation risk | Medium / high | The market often prices the stock at a premium, creating risk if growth targets are missed or multiples compress. |
| Competition risk (Structural Heart) | High | Rivals like Abbott and Medtronic invest heavily to challenge Edwards’ leadership in the TAVR and TMTT markets. |
| Business quality | Strong | The company possesses high barriers to entry due to deep clinical expertise, patent moats, and specialized manufacturing capabilities. |
| Dividend income | Low / none | Investors should not rely on this stock for cash distributions as capital is focused on innovation. |
| Execution risk | Medium | Successful commercialization of new transcatheter therapies depends on complex clinical execution and physician adoption curves. |
Price Behavior
Steady Uptrend
The stock demonstrates consistent and steady upward price momentum.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit -6.85% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 49.74B USD | Price to earnings Ratio 51.36 | 1Y Target Price 100.96 |
Price to earnings Ratio 51.36 | 1Y Target Price 100.96 | ||
Volume (30-day avg) 3.1M shares | Beta 0.85 | 52 Weeks Range 72.30 - 96.29 | Updated Date 09/26/2026 |
52 Weeks Range 72.30 - 96.29 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.68 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Transcatheter Aortic Valve Replacement (TAVR) | SAPIEN family of valves and delivery systems. | This is the primary revenue driver, selling advanced heart valves that replace the need for traditional open-heart surgery. |
| Transcatheter Mitral and Tricuspid Therapies (TMTT) | PASCAL, EVOQUE, and other valve repair/replacement products. | This is the main growth engine, providing new ways to treat complex mitral and tricuspid heart valve issues. |
| Surgical Structural Heart | Traditional surgical valves and repair accessories. | Provides stable, long-term revenue through mature surgical valve products used in standard heart operations. |
| Geography | Global sales split between the US, Europe, and Asia-Pacific. | International expansion, particularly in high-growth Asian markets, is a key component of the company's long-term revenue strategy. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 51.36 | Forward PE 25.64 | Enterprise Value 46.49B | Price to Sales(TTM) 7.64 |
Enterprise Value 46.49B | Price to Sales(TTM) 7.64 | ||
Enterprise Value to Revenue 7.14 | Enterprise Value to EBITDA 28.14 | Shares Outstanding 576.40M | Shares Floating 574.49M |
Shares Outstanding 576.40M | Shares Floating 574.49M | ||
Percent Insiders 0.19 | Percent Institutions 95.73 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Edwards Lifesciences Corp
Exchange NYSE | Headquarters Irvine, CA, United States | ||
IPO Launch date 2000-03-27 | CEO & Director Mr. Bernard J. Zovighian | ||
Sector Healthcare | Industry Medical Devices | Full time employees 16000 | Website https://www.edwards.com |
Full time employees 16000 | Website https://www.edwards.com | ||
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.